Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 511 to 520 of 1655

TitleReference numberPublishedLast updated
PromarkerD for predicting the risk of diabetic kidney disease in people with type 2 diabetesMIB312
Memokath 051 Ureter stent for ureteric obstructionHTG651
Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal)TA848
Mepolizumab for treating eosinophilic granulomatosis with polyangiitis (terminated appraisal)TA845
Mepolizumab for treating severe hypereosinophilic syndrome (terminated appraisal)TA846
Mepolizumab for treating severe chronic rhinosinusitis with nasal polyps (terminated appraisal)TA847
Optilume for treating recurrent bulbar urethral stricturesHTG649
GreenLight XPS for treating benign prostatic hyperplasiaHTG650
Luspatercept for treating anaemia caused by beta-thalassaemia (terminated appraisal)TA843
Luspatercept for treating anaemia caused by myelodysplastic syndromes (terminated appraisal)TA844

Results per page

  1. 10
  2. 25
  3. 50
  4. All